licaminlimab

PreclinicalMonoclonal antibody

OOculis

licaminlimab is one of 3 small molecule programs targeting Dry Eye Disease (DED). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Eye Disease (DED)Recruiting

Dry Eye Disease (DED)Preclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Dry Eye Disease (DED)

#DrugCompanyPhaseTrials

Systane PRO

SScripps Poway Eyecare and Optometry

Phase 3

2 2

DFL24498

DDompé Farmaceutici S.p.A

Phase 2

1 3

licaminlimab

OOculis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Dry Eye Disease (DED)

NCT07548632

Clinical

Trials by Indication[1]

Eye Disease1 trial

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

Completed·OOculis·Phase 2·NCT05896670·122 enrolled

Dry Eye Disease (DED)1 trial

A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype

Recruiting·OOculis·Preclinical·NCT07548632·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for licaminlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — licaminlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for licaminlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oculis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: OOculis

licaminlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Eye Disease1 trial

Dry Eye Disease (DED)1 trial

References

Drug Info

Quick Facts

Related News